Slide 1: Q2 FY26 Earnings presentation
Q2 FY26 Earnings presentation August 5, 2026 © Solventum 2026. All rights reserved.
Slide 2: Forward-looking statements and use of document
Forward-looking statements and use of document This presentation contains or incorporates by reference statements that relate to future events and expectations and, as such, constitute forward-looking statements that involve risk and uncertainties. All statements that reflect Solventum’s expectation
Slide 3: Solventum | roadmap to the mission
Solventum | roadmap to the mission Values Strategic pillars Put people first Be a best & preferred Mission place to work Win with excellence Enabling better, Solve what matters smarter, safer Be a trusted partner healthcare to Advance together improve lives Be a top quartile Live with heart performe
Slide 4: Solventum value creation formula
Solventum value creation formula Attractive set up diverse businesses, attractive markets and strong brands Foundational + enhancements mission, talent, culture, innovation engine (commercial and R&D) market selection and growth drivers – enable sales growth, + Strategic clarity margin expansion and
Slide 5: Key Messages for the Quarter
Key Messages for the Quarter Solid results led Separation by underlying workstreams sales momentum winding down Announced intent Increased full to separate HIS year guidance business Q2 FY2026 Earnings Presentation © Solventum 2026. All rights reserved. 5 2See non-GAAP financial measures and reconci
Slide 6: Q2 FY26 financial summary
Q2 FY26 financial summary Dental Solutions Key metrics $396M +17.0% Reported GAAP Non-GAAP3 +15.2% Organic Operating margin 8.2% 28.4% Health Information Systems TOTAL SOLVENTUM SALES1 MedSurg $354M $1,372M Diluted EPS $0.53 $2.55 +4.4% Reported +5.4% Organic $2,209M +12.7% Reported +2.2% Y/Y Report
Slide 7: MedSurg summary
MedSurg summary AWC $537M | 39% +14.9% Y/Y Rep +7.1% Y/Y Org $1,372M Q2 financial results +12.7% Y/Y Reported +8.9% Y/Y Organic* IP&SS Q2 FY26 Q2 FY25 Y/Y* $836M | 61% +11.3% Y/Y Rep +10.1% Y/Y Org Reported +12.7% Tegaderm CHG (chlorhexidine Net sales $1,372M $1,218M Organic +8.9% gluconate) IV secu
Slide 8: Dental Solutions summary
Dental Solutions summary Solventum Filtek Warmer Kit Composite Easy one-button operation warms Q2 financial results composite material in as little as two minutes with capacity for six capsules and one flowable syringe. Designed Q2 FY26 Q2 FY25 Y/Y* especially for Filtek dental restoratives to achie
Slide 9: Health Information Systems summary
Health Information Systems summary Solventum System 360 Encompass Latest generation coding solution combines coding and reimbursement processes along Q2 financial results with workflow improvements to help hospitals streamline revenue cycle processes, receive accurate reimbursement, Q2 FY26 Q2 FY25
Slide 10: Executing a balanced capital plan
Executing a balanced capital plan Debt paydown Invest for growth Return capital to shareholders • Divested P&F business1; net proceeds • Announced intent to separate HIS, will • In Q2 2026, repurchased 3.9M shares primarily used for debt paydown create a more dedicated MedTech with for total conside
Slide 11: FY2026 financial guidance and considerations
FY2026 financial guidance and Additional 2026 considerations considerations1 ERP timing impact Majority reverses in Q3 Expect most of Q2 Sales $125M & EPS $0.34 benefits will reverse in 2H, with majority in Q3 FX impact net sales Organic sales growth +2.5% to +3.0% ~100bps benefit vs prior range of
Slide 12: Appendix
Appendix Q2 FY2026 Earnings Presentation © Solventum 2026. All rights reserved. 12
Slide 13: Non-GAAP financial measures
Non-GAAP financial measures In addition to reporting financial results in accordance with U.S. GAAP, Solventum also provides non-GAAP measures that we use, and plan to continue using, when monitoring and evaluating operating performance. The adjusted measures are not in accordance with, nor are they
Slide 14: Q2 FY26 non-GAAP reconciliation & free cash flow
Q2 FY26 non-GAAP reconciliation & free cash flow 3M Spin-off & Purification Planned separation of Q2 FY26 Restructuring separation-related Certain litigation- and Filtration Acquisition-related Health Information Q2 FY26 ($ Millions, except per share data) GAAP Amortization costs costs related costs
Slide 15: Glossary and definitions
Glossary and definitions Abbreviation Elaboration Organic sales growth Total net sales less the impacts of foreign currency and sales from business acquisitions or AI Artificial intelligence divestitures for the first 12 months post-transaction Adjusted gross margin AWC Advanced Wound Care Gross mar